Certain Common Stock of SUSMED,Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2022.
March 23, 2022
Share
Certain Common Stock of SUSMED,Inc. are subject to a Lock-Up Agreement Ending on 23-MAR-2022. These Common Stock will be under lockup for 89 days starting from 24-DEC-2021 to 23-MAR-2022.
Details:
The Company's stock acquisition rights holders Tomonobu Hirano, Kosuke Okumura, Junji Kachi, Shinichi Tamura, Kentaro Takashiro, Yosuke Watanabe, Yuko Saito, Keito Omura and Toru Oizumi have agreed not to issue, transfer or sell the Company's common stock held at its own expense or securities that have the right to acquire the Company's common stock (including potential stock) from the date of conclusion of the principal underwriting agreement to March 23, 2022, which is the 90th day from the listing (starting of trading) date, without obtaining the prior written consent of the co-leading managing company.
The Company, have agreed not to issue, transfer or sell the Company's common stock (including potential stock) securities that have the right to acquire stocks, from the date of conclusion of the principal underwriting contract for the sale by the underwriting and the underwriter's purchase transaction to June 21, 2022, which is the 180th day from the listing (start of trading) date (hereinafter referred to as ""lockup""). without the prior written consent of the co-lead managing underwriter.
Susmed Inc is a Japan-based company mainly engaged in the digital therapeutics (DTx) development business. The Company operates through two business segments. The DTx Product segment is engaged in the development of application software products for treating diseases such as insomnia, breast cancer, chronic kidney diseases and others. The DTx Platform segment is engaged in the provision of general-purpose clinical trial systems and machine learning automatic analysis systems, as well as the provision of DTx development support services using systems.
SUSMED,INC. 
